Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2012 13:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at The Immunotherapeutics Partnering and Dealmaking Conference

LAKE OSWEGO, Ore., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
January 24, 2012 13:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the World Cancer Immunotherapy Conference

LAKE OSWEGO, Ore., Jan. 24, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
January 20, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence

NeuVax adjuvant therapy intended for patients not eligible for Herceptin® (trastuzumab) therapy Phase 3 trial being conducted under FDA-approved Special Protocol Assessment; initiated...
January 05, 2012 12:00 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Biotech Showcase 2012 Conference

LAKE OSWEGO, Ore, Jan. 5, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical...
January 05, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Investigational New Drug Approval for Phase 2 Trial for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (trastuzumab)

LAKE OSWEGO, Ore., Jan. 5, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
December 09, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents Phase 2 Trial Design for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (Trastuzumab) at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

Collaborative trial being co-sponsored by Galena Biopharma and Genentech/Roche through the Henry M. Jackson Foundation for the Advancement of Military Medicine Randomized Phase 2 clinical...
December 07, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents 5 Year NeuVax(TM) Efficacy Data at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

LAKE OSWEGO, Ore., Dec. 7, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
December 06, 2011 09:30 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Enters Into Exchange Agreements With Warrant Holders

LAKE OSWEGO, Ore., Dec. 6, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet...
November 28, 2011 16:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the NYSSA 15th Annual Biotech and Specialty Pharmaceuticals Conference

LAKE OSWEGO, Ore., Nov. 28, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
November 28, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Clinical Development Collaboration With Genentech/Roche and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) for NeuVax(TM) (E75) Combined With Herceptin(R) (trastuzumab) in Adjuvant Breast Cancer

Randomized Phase 2 clinical study in 300 patients for adjuvant breast cancer to commence in 1H, 2012. Additional clinical study expands potential uses for NeuVax™ in combination...